Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised …
…, HP Tony, S Kleinert, M Feuchtenberger… - Annals of the …, 2016 - ard.bmj.com
Objective To prospectively analyse the risk for disease relapses in patients with rheumatoid
arthritis (RA) in sustained remission, either continuing, tapering or stopping disease-…
arthritis (RA) in sustained remission, either continuing, tapering or stopping disease-…
Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre …
…, K Boche, GR Burmester, A Engel, M Feuchtenberger… - The Lancet, 2020 - thelancet.com
Background Patients with inflammatory diseases, such as rheumatoid arthritis, often receive
glucocorticoids, but long-term use can produce adverse effects. Evidence from randomised …
glucocorticoids, but long-term use can produce adverse effects. Evidence from randomised …
Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment
…, M Ronneberger, M Feuchtenberger… - Annals of the …, 2016 - ard.bmj.com
Objective To analyse the role of multibiomarker disease activity (MBDA) score in predicting
disease relapses in patients with rheumatoid arthritis (RA) in sustained remission who …
disease relapses in patients with rheumatoid arthritis (RA) in sustained remission who …
[HTML][HTML] Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling
…, I Singh, C Fan, X Liu, M Rau, M Feuchtenberger… - Journal of …, 2023 - Elsevier
Background & Aims The progression of non-alcoholic steatohepatitis (NASH) to fibrosis and
hepatocellular carcinoma (HCC) is aggravated by auto-aggressive T cells. The gut-liver axis …
hepatocellular carcinoma (HCC) is aggravated by auto-aggressive T cells. The gut-liver axis …
Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic …
…, M Ronneberger, M Feuchtenberger… - Annals of the …, 2017 - ard.bmj.com
Objective To perform a detailed analysis of the autoantibody response against post-translationally
modified proteins in patients with rheumatoid arthritis (RA) in sustained remission and …
modified proteins in patients with rheumatoid arthritis (RA) in sustained remission and …
[HTML][HTML] Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German …
…, HP Tony, A Krause, M Feuchtenberger… - Rheumatology …, 2012 - Springer
The objective of this study was to use data from a noninterventional study to evaluate the
effectiveness of adalimumab in rheumatoid arthritis (RA) patients during routine clinical practice …
effectiveness of adalimumab in rheumatoid arthritis (RA) patients during routine clinical practice …
Micronodular thymoma: an epithelial tumour with abnormal chemokine expression setting the stage for lymphoma development
The aetiology of primary B‐cell lymphomas of the thymus is enigmatic. Although thymic
follicular lymphoid hyperplasia (TFH) is commonly associated with myasthenia gravis (MG), …
follicular lymphoid hyperplasia (TFH) is commonly associated with myasthenia gravis (MG), …
Vaccination survey in patients with rheumatoid arthritis: a cross-sectional study
M Feuchtenberger, S Kleinert, S Schwab, P Roll… - Rheumatology …, 2012 - Springer
The objective of this study is to evaluate the vaccination status in rheumatoid arthritis (RA)
patients during routine clinical practice, data from a German non-interventional cross-sectional …
patients during routine clinical practice, data from a German non-interventional cross-sectional …
Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trial
…, JF Cobra, M Feuchtenberger… - The Lancet …, 2021 - thelancet.com
Background Owing to increasing remission rates, the management of patients with rheumatoid
arthritis in sustained remission is of growing interest. The Rheumatoid Arthritis in Ongoing …
arthritis in sustained remission is of growing interest. The Rheumatoid Arthritis in Ongoing …
Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo …
…, DM Kofler, F Behrens, M Feuchtenberger… - The Lancet, 2024 - thelancet.com
Background Individuals with anti-citrullinated protein antibodies (ACPAs) and subclinical
inflammatory changes in joints are at high risk of developing rheumatoid arthritis. Treatment …
inflammatory changes in joints are at high risk of developing rheumatoid arthritis. Treatment …